Cargando…
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease
BACKGROUND: Untreated, chronic hepatitis C virus (HCV) infection may lead to progressive liver damage, which can be mitigated by successful treatment. This integrated analysis reports the safety, efficacy, and pharmacokinetics (PK) of the ribavirin-free, direct-acting, antiviral, fixed-dose combinat...
Autores principales: | Gane, Edward, Poordad, Fred, Zadeikis, Neddie, Valdes, Joaquin, Lin, Chih-Wei, Liu, Wei, Asatryan, Armen, Wang, Stanley, Stedman, Catherine, Greenbloom, Susan, Nguyen, Tuan, Elkhashab, Magdy, Wörns, Marcus-Alexander, Tran, Albert, Mulkay, Jean-Pierre, Setze, Carolyn, Yu, Yao, Pilot-Matias, Tami, Porcalla, Ariel, Mensa, Federico J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6821220/ https://www.ncbi.nlm.nih.gov/pubmed/30923816 http://dx.doi.org/10.1093/cid/ciz022 |
Ejemplares similares
-
Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older
por: Foster, Graham R., et al.
Publicado: (2019) -
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment
por: Poordad, Fred, et al.
Publicado: (2017) -
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure
por: Poordad, Fred, et al.
Publicado: (2018) -
Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection
por: Ng, Teresa I., et al.
Publicado: (2018) -
Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study
por: Fontana, Robert J., et al.
Publicado: (2019)